EP2560649 - PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 10.02.2017 Database last updated on 02.09.2024 | |
Former | Examination is in progress Status updated on 03.11.2016 | Most recent event Tooltip | 10.02.2017 | Application deemed to be withdrawn | published on 15.03.2017 [2017/11] | Applicant(s) | For all designated states Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US | [2014/35] |
Former [2014/09] | For all designated states Vertex Pharmaceuticals Inc. 50 Northern Avenue Boston, MA 02210 / US | ||
Former [2013/09] | For all designated states Vertex Pharmaceuticals Incorporated 130 Waverly Street Cambridge, MA 02139 / US | Inventor(s) | 01 /
VAN GOOR, Fredrick, F. 832 Ormond Court San Diego, CA 92109 / US | 02 /
ALARGOVA, Rossitza, Gueorguieva 148 Newton Street, Apt. 4 Brighton, MA 02135 / US | 03 /
ALCACIO, Tim, Edward 2276 Fenton Parkway, 304 San Diego, CA 92108 / US | 04 /
AREKAR, Sneha, G. 26 Waverly Street, Apt. 209 Brighton, MA 02135 / US | 05 /
JOHNSTON, Steven, C. 22 Page Road Lichtfield, NH 03052 / US | 06 /
KADIYALA, Irina, Nikolaevna 40 Hagen Road Newton, MA 02457 / US | 07 /
KESHAVARZ-SHOKRI, Ali 4285 Corte Langostino San Diego, CA 92130 / US | 08 /
KRAWIEC, Mariusz 46 Littlefield Lane Marlborough, MA 01752 / US | 09 /
LEE, Elaine, Chungmin 303 Third Street Apt.316 Cambridge, MA 02142 / US | 10 /
MEDEK, Ales 14 Lockland Road Winchester, MA 01890 / US | 11 /
MUDUNURI, Praveen 7 Charlesbank Way, Apt. A Waltham, MA 02453 / US | 12 /
SULLIVAN, Mark, Jeffrey 103 Howe Street Framingham, MA 01702 / US | 13 /
ZAMAN, Noreen, Tasneem 1 Magnolia Drive Acton, MA 01720 / US | 14 /
ZHANG, Beili 4505 Shorepointe Way San Diego, CA 92130 / US | 15 /
ZHANG, Yuegang 15 Fairfield Road Wayland, MA 01778 / US | 16 /
ZLOKARNIK, Gregor 2754 Palomino Circle La Jolla, CA 92037 / US | [2013/09] | Representative(s) | Oates, Edward Christopher, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2014/45] |
Former [2014/44] | Goodfellow, Hugh Robin, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | ||
Former [2013/09] | Cohausz & Florack Patent- und Rechtsanwälte Partnerschaftsgesellschaft Bleichstraße 14 40211 Düsseldorf / DE | Application number, filing date | 11718596.7 | 22.04.2011 | WO2011US33687 | Priority number, date | US20100329510P | 29.04.2010 Original published format: US 329510 P | US20100327078P | 22.04.2010 Original published format: US 327078 P | US20100327091P | 22.04.2010 Original published format: US 327091 P | [2013/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2011133951 | Date: | 27.10.2011 | Language: | EN | [2011/43] | Type: | A1 Application with search report | No.: | EP2560649 | Date: | 27.02.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.10.2011 takes the place of the publication of the European patent application. | [2013/09] | Search report(s) | International search report - published on: | EP | 27.10.2011 | Classification | IPC: | A61K31/4704, A61K31/404, A61K31/443 | [2013/09] | CPC: |
A61K31/47 (EP,US);
A61K31/404 (EP,US);
A61K31/443 (EP,US);
A61K31/4433 (EP,US);
A61K31/4704 (EP,US);
A61P1/16 (EP);
A61P1/18 (EP);
A61P11/00 (EP);
A61P11/06 (EP);
A61P25/16 (EP);
A61P25/28 (EP);
A61P3/10 (EP);
| C-Set: |
A61K31/404, A61K2300/00 (EP,US);
A61K31/4433, A61K2300/00 (US,EP);
A61K31/443, A61K2300/00 (US,EP);
A61K31/4704, A61K2300/00 (EP,US); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/09] | Extension states | BA | 06.11.2012 | ME | 06.11.2012 | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND IHRE VERABREICHUNG | [2013/09] | English: | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | [2013/09] | French: | COMPOSITIONS PHARMACEUTIQUES ET LEURS ADMINISTRATIONS | [2013/09] | Entry into regional phase | 06.11.2012 | National basic fee paid | 06.11.2012 | Designation fee(s) paid | 06.11.2012 | Examination fee paid | Examination procedure | 06.11.2012 | Examination requested [2013/09] | 06.06.2013 | Amendment by applicant (claims and/or description) | 17.04.2014 | Despatch of a communication from the examining division (Time limit: M04) | 27.08.2014 | Reply to a communication from the examining division | 30.03.2015 | Despatch of a communication from the examining division (Time limit: M06) | 15.01.2016 | Reply to a communication from the examining division | 27.05.2016 | Despatch of a communication from the examining division (Time limit: M04) | 07.10.2016 | Application deemed to be withdrawn, date of legal effect [2017/11] | 04.11.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2017/11] | Divisional application(s) | EP16192470.9 / EP3138563 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 17.04.2014 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 15.01.2016 | Request for further processing filed | 15.01.2016 | Full payment received (date of receipt of payment) Request granted | 09.02.2016 | Decision despatched | Fees paid | Renewal fee | 29.04.2013 | Renewal fee patent year 03 | 28.04.2014 | Renewal fee patent year 04 | 10.04.2015 | Renewal fee patent year 05 | 29.09.2016 | Renewal fee patent year 06 | Penalty fee | Additional fee for renewal fee | 30.04.2016 | 06   M06   Fee paid on   29.09.2016 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2006002421 (VERTEX PHARMA [US], et al) [Y] 1-22 * page 52; example 136 * * pages 25,65; example 475 * * page 100, paragraphs 275-276 *; | [Y]WO2007056341 (VERTEX PHARMA [US], et al) [Y] 1-22 * page 96; example 418 * * page 107, paragraph 338 *; | [Y]WO2007079139 (VERTEX PHARMA [US], et al) [Y] 1-22 * page 43, paragraph 199; claim - *; | [Y]WO2007117715 (VERTEX PHARMA [US], et al) [Y] 1-22 * page 62; example 302 * * page 94, paragraph 257 *; | [Y]WO2009023509 (VERTEX PHARMA [US], et al) [Y] 1-22 * page 40; compound 433 * * page 8, paragraph 29 *; | [Y]WO2009038683 (VERTEX PHARMA [US], et al) [Y] 1-22 * page 44; claim - *; | [Y]US2009131492 (RUAH SARA S HADIDA [US], et al) [Y] 1-22 * pages 25,85,87 * * page 113, paragraph 296 *; | [XY]WO2009073757 (VERTEX PHARMA [US], et al) [X] 1,2,5,6,8-22 * page 18, paragraph 105 * [Y] 1-22; | [XY]WO2009076141 (VERTEX PHARMA [US], et al) [X] 1,2,5,6,8-22 * page 22, paragraph 116 * [Y] 1-22; | [XY]WO2010037066 (VERTEX PHARMA [US], et al) [X] 1,2,5,6,8-22 * page 22, paragraph 108 * [Y] 1-22; | [XPY]WO2010053471 (VERTEX PHARMA [US], et al) [XP] 1,3,5,7-22 * page 37, paragraph 109 * [Y] 1-22; | [XPY]WO2010054138 (VERTEX PHARMA [US], et al) [XP] 1,3,5,7-22 * page 72 * [Y] 1-22; | [A] - JONES ANDREW M ET AL, "Emerging Treatments in Cystic Fibrosis", DRUGS, ADIS INTERNATIONAL LTD, NZ, (20090101), vol. 69, no. 14, doi:DOI:10.2165/11318500-000000000-00000, ISSN 0012-6667, pages 1903 - 1910, XP008134754 [A] 1-22 * page 1907, column r * DOI: http://dx.doi.org/10.2165/11318500-000000000-00000 | by applicant | US5304121 | US5886026 | US6099562 | US2003144257 | US2004006237 | US2004105820 | WO2005075435 | WO2006002421 | US2008306062 | US7495103 | US2009099230 | US2009105272 | US2009131492 | US7553855 | US2009170905 | US2009176839 | US2009246820 | US7645789 | US7659268 | US2010074949 | US2010087490 | US7741321 | US2010184739 | US7776905 | US2010256184 | US2010267768 | US2011065928 | US2011064811 | - GREGORY, R. J. ET AL., NATURE, (1990), vol. 347, pages 382 - 386 | - RICH, D. P. ET AL., NATURE, (1990), vol. 347, pages 358 - 362 | - RIORDAN, J. R. ET AL., SCIENCE, (1989), vol. 245, pages 1066 - 1073 | - CUTTING, G. R. ET AL., NATURE, (1990), vol. 346, pages 366 - 369 | - DEAN, M. ET AL., CELL, (1990), vol. 61, pages 863 - 870 | - KEREM, B-S. ET AL., SCIENCE, (1989), vol. 245, pages 1073 - 1080 | - KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 8447 - 8451 | - QUINTON, P. M., FASEB J., (1990), vol. 4, pages 2709 - 2727 | - DALEMANS ET AL., NATURE LOND., (1991), vol. 354, pages 526 - 528 | - PASYK, FOSKETT, J. CELL. BIOCHEM., (1995), vol. 270, pages 12347 - 50 | - HWANG, T. C. ET AL., J. GEN. PHYSIOL., (1998), vol. 111, no. 3, pages 477 - 90 | - SHELDRICK, G.M., ACTA CRYST., (2008), vol. A64, pages 112 - 122 | - SHELDRICK,G.M., ACTA CRYST., (2008), vol. A64, pages 112 - 122 | - S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, (1977), vol. 66, pages 1 - 19 | - LEE R. CHOO-KANG, PAMELA L., "Zeitlin, Type I, II, III, N, and V cystic fibrosis Transmembrane Conductance Regulator Defects and Opportunities of Therapy", CURRENT OPINION IN PULMONARY MEDICINE, (2000), vol. 6, pages 521 - 529 | - GALIETTA, L.J.V., LANTERO, S., GAZZOLO, A., SACCO, O., ROMANO, L., ROSSI, G.A., ZEGARRA-MORAN, O., IN VITRO CELL. DEV. BIOL., (1998), vol. 34, pages 478 - 481 | - RAE, J., COOPER, K., GATES, P., WATSKY, M., J. NEUROSCI. METHODS, (1991), vol. 37, pages 15 - 26 | - DALEMANS, W., BARBRY, P., CHAMPIGNY, G., JALLAT, S., DOTT, K., DREYER, D., CRYSTAL, R.G., PAVIRANI, A., LECOCQ, J-P., LAZDUNSKI, M, NATURE, (1991), vol. 354, pages 526 - 528 | - GONZALEZ, J. E., R. Y. TSIEN, "Voltage sensing by fluorescence resonance energy transfer in single cells", BIOPHYS J, (1995), vol. 69, no. 4, pages 1272 - 80 | - GONZALEZ, J. E., R. Y. TSIEN, "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer", CHEM BIOL, (1997), vol. 4, no. 4, pages 269 - 77 | - GONZALEZ, J. E., K. OADES ET AL., "Cell-based assays and instrumentation for screening ion-channel targets", DRUG DISCOV TODAY, (1999), vol. 4, no. 9, pages 431 - 439 |